ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
News Apr 16, 2012
ElexoPharm GmbH has announced the appointment of Dr. Chris J. van Koppen as Head of Research.
He will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.
Dr. van Koppen holds a Ph.D. in Pharmacology and brings extensive industry experience in drug discovery.
Before joining ElexoPharm in January 2012, he served as Leader of four lead optimization projects at Merck Sharp & Dohme, The Netherlands.
He was responsible for delivery of candidate drugs for preclinical development in endocrinological diseases.
Dr. van Koppen was also strongly involved in assay development, HTS, lead finding and proof-of-concept projects.
Before working at MSD, Dr. van Koppen was independent group leader at the Universitätsklinikum Essen and received his Habilitation in Pharmacology and Toxicology.
He has published almost 70 peer-reviewed research papers, including publications in high IF journals (J Biol Chem, Endocrinology, J Clin Endocrinol Metab, PNAS, Mol Pharmacol, Br J Pharmacol, Thorax, Pharmacol Ther, and EMBO Journal).
Axel Koch, Managing Director of ElexoPharm, said: “We are delighted to have such an experienced scientist as Head of Research. His expertise in successfully leading preclinical drug discovery projects will strongly advance our innovative portfolio.”
Dr. van Koppen adds: “I am thrilled to work in the dynamic team of ElexoPharm on highly innovative projects to design and develop drugs for the treatment of endocrinological, cardiovascular and neoplastic diseases.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018